Company Partners With NIH to Identify Research Programs
5 Feb 2015
Pfizer and the U.S. National Institutes of Health plan to conduct collaborative research programs focused on translating research into clinical applications.
Through the partnership, announced on Dec. 4, 2014, Pfizer's Centers for Therapeutic Innovation (CTI) is partnering with NIH's National Center for Advancing Translations Sciences (NCATS) in an effort designed to help bridge a gap that exists between early scientific discovery and its translation into new medicines.
With this agreement, the NIH has become the first U.S. government agency to enter into a collaborative agreement to conduct research through Pfizer's CTI network.
"Forging novel collaborations has become the key to unlocking the scientific potential that exists within industry, academia, and government," said Mikael Dolsten, President of Worldwide Research and Development.
"In this first-of-its-kind collaboration, Pfizer's CTI and NIH's NCATS bring a tremendous amount of scientific fortitude that we hope will translate into transformative therapies for patients."
As part of the agreement, the partners could enter into several research collaborations that combine NIH intramural investigators' knowledge of biological mechanisms with Pfizer's preclinical and clinical development
expertise. In addition to NIH, the CTI network includes 25 academic institutions and five patient foundations.